Beyond Meat (NASDAQ:BYND) Misses Q1 Revenue Estimates, Stock Drops
Plant-based protein company Beyond Meat (NASDAQ:BYND) missed Wall Street's revenue expectations in Q1 CY2025, with sales falling 9.1% year on year to $68.73 million. Its non-GAAP loss of $0.67 per share was 41.3% below analysts' consensus estimates.
Is now the time to buy Beyond Meat? Find out in our full research report.
Beyond Meat (BYND) Q1 CY2025 Highlights:
Revenue: $68.73 million vs analyst estimates of $74.92 million (9.1% year-on-year decline, 8.3% miss)
Adjusted EPS: -$0.67 vs analyst expectations of -$0.47 (41.3% miss)
Adjusted EBITDA: -$42.33 million vs analyst estimates of -$22.13 million (-61.6% margin, 91.3% miss)
Operating Margin: -81.8%, down from -70.7% in the same quarter last year
Free Cash Flow was -$30.63 million compared to -$33 million in the same quarter last year
Sales Volumes fell 11.2% year on year (-16.1% in the same quarter last year)
Market Capitalization: $192.5 million
Beyond Meat President and CEO Ethan Brown commented, 'As the first quarter of 2025 progressed to a close, we saw a slowdown in consumption as the uncertain macroeconomic environment likely exacerbated category challenges. Nevertheless, we drove year-over-year reductions in operating expenses, notwithstanding the impact of certain transitory items, to partially offset disappointing net revenues and gross profit.'
Company Overview
A pioneer at the forefront of the plant-based protein revolution, Beyond Meat (NASDAQ:BYND) is a food company specializing in alternatives to traditional meat products.
Sales Growth
Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but many enduring ones grow for years.
With $319.6 million in revenue over the past 12 months, Beyond Meat is a small consumer staples company, which sometimes brings disadvantages compared to larger competitors benefiting from economies of scale and negotiating leverage with retailers.
As you can see below, Beyond Meat struggled to generate demand over the last three years. Its sales dropped by 11.8% annually as consumers bought less of its products.
Beyond Meat Quarterly Revenue
This quarter, Beyond Meat missed Wall Street's estimates and reported a rather uninspiring 9.1% year-on-year revenue decline, generating $68.73 million of revenue.
Looking ahead, sell-side analysts expect revenue to grow 1.8% over the next 12 months. Although this projection indicates its newer products will spur better top-line performance, it is still below the sector average.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ('Gyre') (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that the first volunteer has been successfully dosed in a Phase 1 clinical trial evaluating F230, a novel endothelin A ('ETA') receptor antagonist, for the treatment of pulmonary arterial hypertension ('PAH').This milestone marks Gyre's entry into the PAH field, a rare, progressive, and high-mortality cardiovascular condition with limited treatment options. PAH is recognized in China's National Rare Disease Catalog, underscoring its significance in public health. According to Frost & Sullivan, China's PAH market was valued at $370 million in 2023 and is projected to grow to $480 million by 2031.F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this pathway, F230 is designed to reduce pulmonary vascular remodeling and lower pulmonary pressure, key contributors to PAH Phase 1 trial is designed to evaluate safety, tolerability, and pharmacokinetics in healthy volunteers. The trial represents the latest expansion of Gyre's fibrosis-first strategy beyond the liver, leveraging a robust clinical development platform and commercial infrastructure in China.F230 joins Gyre's pipeline alongside lead candidate Hydronidone (F351), which met the primary endpoint in a pivotal Phase 3 trial for CHB-fibrosis. A New Drug Application ('NDA') submission to China's National Medical Products Administration ('NMPA') is planned for the third quarter of 2025, and a pre-IND meeting with the U.S. Food and Drug Administration is being planned for an expected Phase 2 trial in metabolic dysfunction-associated steatohepatitis ('MASH') Gyre TherapeuticsGyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis, including MASH, in the U.S. Gyre's strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the People's Republic of China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and StatementsThis press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning the expectations regarding Gyre's research and development efforts and timing of expected clinical trials, including an NDA submission to the NMPA for F351, the expected clinical benefits of F230 and expectations regarding interactions with regulators. In some cases, you can identify forward-looking statements by terms such as 'may,' 'might,' 'will,' 'objective,' 'intend,' 'should,' 'could,' 'can,' 'would,' 'expect,' 'believe,' 'design,' 'estimate,' 'predict,' 'potential,' 'plan' or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre's ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre's capital resources and its ability to raise additional capital. Additional risks and factors are identified under 'Risk Factors' in Gyre's Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings Gyre may make with the SEC. Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by Contact:David ZhangGyre in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
37 minutes ago
- Business Wire
Leap and Xos Partner to Power the Grid with Electric Fleets
SAN FRANCISCO & LOS ANGELES--(BUSINESS WIRE)-- Leap, the leading platform for building and scaling virtual power plants (VPPs), and Xos, Inc., (NASDAQ:XOS), a leading electric truck manufacturer and fleet services provider, today announced a new partnership to unlock grid revenue opportunities for electrified fleets. By connecting Xos Hub charging technology to energy markets through Leap's automated platform, the companies will create new value for fleet owners and deliver crucial support for the grid during energy emergencies. By connecting Xos Hub charging technology to energy markets through Leap's automated platform, the companies will create new value for fleet owners and deliver crucial support for the grid during energy emergencies. Share Xos manufactures electric stepvan vehicles used by some of the country's most recognizable logistics companies, including FedEx and UPS. The company's Xos Hub is a mobile, battery-integrated charger designed to speed up fleet electrification without the delays or costs of traditional infrastructure. It provides a versatile, scalable solution for stopgap charging, remote deployments, semi-permanent charging, and backup power. Now, by using Leap's software-only VPP platform, Xos can enroll its customers in California's Demand Side Grid Support (DSGS) grid services program. During emergency grid events, participating fleets will automatically shift charging from the grid to their Xos Hub battery-integrating chargers, relieving grid strain while generating revenue. Last summer, with major contributions from Leap, DSGS helped California avoid blackouts during prolonged heatwaves. With the addition of Xos's rapidly growing portfolio, Leap and its partners are poised to scale their impact and deliver even greater support to the grid. 'Leveraging our complementary technologies, Leap and Xos are tapping new value streams for commercial truck fleets, the transportation services that power our economy,' said Jason Michaels, CEO of Leap. 'Together, we're making these fleets cleaner, smarter, and more cost effective, while contributing to a more resilient energy landscape.' Leap's universal API suite automates energy market operations, enabling Xos to quickly deploy and scale its own VPP offering without additional hardware or significant additional operational overhead. This means that Xos can immediately start generating new grid revenue, reducing the total product cost for customers and driving ongoing energy savings. 'Our VPP offering gives fleet customers advanced energy capabilities without compromising control or convenience,' said Dakota Semler, CEO of Xos, Inc. 'It's a powerful way to lower the cost of infrastructure ownership even further, maximize the value of our products, and support customers in meeting their electrification goals.' About Leap Leap is the leading platform for launching and scaling virtual power plants (VPPs). Through its software-only solution, Leap facilitates fast, easy and automated access to demand response and other grid services revenue streams for the providers of battery storage systems, EV chargers, smart building technologies, and other distributed energy resources (DERs). Managing over 200,000 energy sites and devices across U.S. energy markets, Leap empowers more than 90 technology partners and their customers to unlock new value and help create a more flexible, resilient grid powered by renewable resources. Visit to learn more. About Xos, Inc. Xos is a leading technology company, electric truck manufacturer, and fleet services provider for battery-electric fleets. Xos vehicles and fleet management software are purpose-built for medium- and heavy-duty commercial vehicles that travel on last-mile, back-to-base routes. The company leverages its proprietary technologies to provide commercial fleets with battery-electric vehicles that are easier to maintain and more cost-efficient on a total cost of ownership (TCO) basis than their internal combustion engine counterparts. For more information, visit
The Verge
37 minutes ago
- The Verge
Microsoft is moving its Build conference out of Seattle for 2026
Microsoft isn't planning to host its Build developer conference in its home city of Seattle next year. The conference is being relocated, and Microsoft has reportedly canceled all its holds for Build at the Seattle convention center 'for all future years.' 'Our plans for Build 2026 have changed, but our vision to empower builders and developers at a major event next year remains unchanged,' said an unnamed Microsoft spokesperson in a statement to The Seattle Medium. 'We appreciate the city and community for their support over the years.' We asked Microsoft to clarify why it's moving out of Seattle, but the company provided the same statement. It's not clear where Build will be located next year, or even if Microsoft may decide to make it an online-only event. The Seattle Medium reports that the decision to move Build could have been related to attendee experiences in downtown Seattle. It cites an unnamed email that claims Build attendees had 'cited the general uncleanliness of the streets, visible drug use, and the presence of unhoused individuals.' Microsoft has held Build in Seattle since 2017, apart from the pandemic years of 2020 to 2022 when it was online-only. Build originally started as a successor for the company's Professional Developers Conference (PDC) and MIX events in 2011, and was held initially in the Anaheim convention center in California. Microsoft then hosted Build on its own campus in 2012, before moving the developer conference to the Moscone Center in San Francisco for four years. Attendees at Build this year were met with heavier security than usual as hundreds of protesters outside the venue gathered to protest against Microsoft's contracts with the Israeli government. Protesters released balloons with alarms attached, unfurled banners, dropped leaflets, and even disrupted Microsoft's Build keynotes and sessions.
